The CFO's Business Case for Passive Monitoring: Three Revenue Lines Your Network Is Already Funding

When a network COO asks "$50 × 1,000 patients × 12 months — that's $600k a year. What's the return?", that is the right first question to ask of any software subscription. Every serious evaluation starts there.

The answer is a revenue line that does not yet sit in most IP clinic P&Ls: recaptured revenue from patients who would otherwise drop out of TMS, discontinue Spravato, or silently relapse between visits. The medical director side of the C-suite sees this in the clinic every day — patients who complete 28 of 36 TMS sessions, patients who miss their 3rd-month Spravato maintenance, patients who stop responding to PHQ-9 emails. The clinical team knows attrition is happening. The finance side does not yet have a reporting line that captures what that attrition costs.

This post builds that line, with peer-reviewed sources, and shows how the $600k cost converts to a 3–4× revenue multiple across a 25-clinic network.

Both views are correct. They are describing the same business. The article connects them.

The three revenue lines passive monitoring unlocks

In a TMS + Spravato clinic, continuous between-visit monitoring creates three distinct revenue lines, each backed by a specific mechanism and a peer-reviewed baseline:

Each line has a different mechanism, but they share a common root cause: the clinic has no continuous visibility into what is happening to the patient between visits. The deterioration-to-dropout cycle completes before anyone can intervene. Passive monitoring closes that visibility gap — and each closure maps directly to revenue the clinic has already earned the right to bill for.

The network math

The default inputs in our network ROI calculator are drawn from published US benchmarks, not marketing-optimistic assumptions: 200 active TMS + Esketamine patients per clinic, 60/40 TMS/Esketamine split, baseline retention rates straight from the peer-reviewed literature, and moderate documented improvements.

Run that through the revenue math for a 25-clinic network — remembering that a 200-patient clinic sits in Tier 3 pricing ($30 per patient-month), not the list $50:

The pricing note matters. At the 151+ patient tier, the per-patient-month rate is $30, not $50 — so a 200-patient clinic pays roughly $50k per year, not $85k. For a single clinic, that means $250k–$350k recovered against ~$50k annual cost — a 5–7× revenue multiple, payback inside three months.

The arithmetic does not rely on optimistic assumptions. It is the delta between peer-reviewed baseline retention rates and documented moderate improvement, applied to revenue the clinics have already earned the right to bill for — at the price point that actually applies to networks at scale.

Why this line is missing from most IP clinic P&Ls

Missed revenue is not a standard accounting category. Billing systems capture sessions billed, courses completed, and collections received. They do not capture "sessions that should have been billed if the patient had not discontinued" — because there is no transaction to record.

That is not a failure of the finance function. It is a structural gap in how clinical attrition gets reported across every specialty that bills per session or per course. The visible costs — FTEs, subscriptions, equipment — get scrutinized because they appear in the ledger. The invisible cost of a Spravato cohort that decays from 100 to 20 patients over 12 months appears only as "normal attrition," and normal attrition is not a line item.

The useful comparison, then, is not the $50 per patient-month fee against peer software prices. It is the $50 per patient-month fee against the dollar value of the clinic's current baseline retention numbers. The numbers below are the building blocks for that comparison.

The pricing tiers are designed to track your scale

Pricing is volume-sensitive by design. The list $50 per patient-month is the small-clinic rate. For any site above 151 active patients — which covers effectively every mid-sized or network clinic — the price drops 40% to $30 per patient-month. This is the number network CFOs should model against, not the list price.

Network-level conversations then get custom arrangements that reflect scale, deployment velocity, and co-development potential — further below the $30 tier for large multi-site rollouts. List prices are the starting point, not the anchor. For a 25-clinic operator, the effective per-patient rate typically lands below $30.

A three-input model for your own P&L

The calculator runs every permutation automatically, but here are the three inputs a finance team needs to plug in from their own data to build the recaptured-revenue line directly:

Plug those three numbers into your own model. The calculator below does the same thing with our default assumptions — useful as a sanity check or starting point.

The strategic framing

One network medical director summarized the value to their C-suite in one sentence: passive monitoring converts the patients we were already going to lose into the patients we keep treating. That is the frame that makes the finance math snap into place.

This is not a digital health story about "better patient engagement" — that framing sells the product short and sells the economics backwards. This is a revenue recovery story. The clinical benefit to the patient is real, validated across 10+ studies, and is the reason medical directors advocate for it. The financial benefit to the network is what makes it deployable at scale. Both are true. Both are why interventional psychiatry is, in our view, the specialty where passive monitoring transitions from a promising idea to a standard-of-care expectation over the next 24 months.